NAD+ and NMN Supplements: Higher NAD+ Without Longevity Proof

The premise

NAD+ is a molecule every cell uses for energy and repair, and its levels decline with age. The longevity pitch is simple: take a precursor like NMN (nicotinamide mononucleotide) to refill NAD+ and slow aging. The biology is real; the human evidence is younger than the marketing.

What NAD+ does, in plain words

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme - a helper molecule - that shuttles electrons in the reactions that turn food into usable energy. It is also the fuel for a family of enzymes that do maintenance work: sirtuins, which regulate metabolism and stress responses, and PARPs, which repair damaged DNA. Because those enzymes consume NAD+ as they work, and because enzymes such as CD38 that break NAD+ down are thought to become more active with age, tissue NAD+ levels fall gradually in both rodents and humans (Covarrubias et al. 2021). Levels in skin, blood, liver, muscle and brain are all thought to decline with age (Song et al. 2023).

NMN sits one step before NAD+ in the main recycling pathway, which is why swallowing it can raise blood NAD+. The same review that lays out this biology is candid about the gap: how NAD+ influences human ageing, how best to restore it, whether doing so is safe long-term and whether it helps ageing humans at all “remains to be learnt” - the field’s own words, not a sceptic’s.

Where the excitement came from: mice

The most dramatic results are in mice. In the foundational study, NMN given orally for 12 months to normally ageing mice suppressed age-related weight gain, improved energy metabolism, physical activity, insulin sensitivity and eye function, with no obvious toxicity (Mills et al. 2016). Note what it did not test: lifespan. Even in mice, “slowed some markers of ageing” is the finding, not “lived longer.”

What human trials show

Biochemically, NMN does what it claims - studies confirm oral NMN raises blood NAD+ levels and is well tolerated at doses up to about 500 mg/day (Song et al. 2023). Early trials hint at modest benefits: one found improved muscle function in older men (Igarashi et al. 2022), and small studies report changes in metabolic and vascular markers.

The trials themselves, in order of what they found:

• First safety study (Irie et al. 2020): single doses of 100, 250 or 500 mg in 10 healthy Japanese men. No changes in heart rate, blood pressure or other clinical measures; NMN metabolites rose in blood in a dose-dependent way.
• Prediabetic women (Yoshino et al. 2021): 25 postmenopausal women with prediabetes who were overweight or obese took 250 mg/day or placebo for 10 weeks (13 NMN, 12 placebo). Muscle insulin sensitivity, measured with the gold-standard clamp technique, rose about 25% in the NMN group and did not change on placebo. Body weight, fasting glucose, HbA1c and blood lipids did not change - the effect was on a research measurement, not on anything a doctor would see on a blood test.
• Older men (Igarashi et al. 2022): 250 mg/day for 6 or 12 weeks in a placebo-controlled trial. Blood NAD+ rose; gait speed and left-hand grip strength improved “nominally,” which the authors say should be validated in larger studies; body composition did not change. Several authors were employees of the NMN manufacturer.
• Healthy volunteers (Okabe et al. 2022): 30 healthy adults, 250 mg/day or placebo for 12 weeks. Blood NAD+ rose significantly; no adverse effects or laboratory abnormalities.
• Dose-ranging trial (Yi et al. 2023): 80 healthy middle-aged adults took placebo, 300, 600 or 900 mg/day for 60 days. Blood NAD+ rose at every dose and was highest in the 600 and 900 mg groups. Six-minute walking distance improved more than placebo at all doses, and a blood-based “biological age” estimate rose in the placebo group but not in the NMN groups. Insulin resistance (HOMA-IR) did not differ. No safety issues up to 900 mg/day. Several authors were employees of the manufacturer.
• Arterial stiffness (Katayoshi et al. 2023): 36 healthy middle-aged adults, 125 mg twice daily for 12 weeks. Pulse-wave velocity “tended to decrease” but the difference from placebo was not statistically significant.

For comparison, the related precursor nicotinamide riboside (NR) has a similar record: a 6-week crossover trial in healthy middle-aged and older adults found it well tolerated and effective at raising NAD+, with only preliminary hints on blood pressure (Martens et al. 2018). How the two compare is covered in NMN vs NR.

The honest caveat: the most dramatic results are in mice, human trials are small, short, and mixed, and whether raising NAD+ actually extends healthspan or lifespan in people is not established.

Where the evidence is weak

• Size and length. The largest trial had 80 people; the longest ran 12 weeks. Ageing plays out over decades.
• Surrogate endpoints. Every positive human result is a biomarker or a performance test - NAD+ in blood, a walking test, a clamp measurement, an algorithmic “biological age.” None is a health outcome.
• Mixed signals. The dose-ranging trial that measured insulin resistance with the HOMA-IR blood index found nothing; the one that used a clamp found something. Grip strength improved on one hand only. Arterial stiffness moved in the right direction but not significantly.
• Funding. Most trials were run or funded by NMN manufacturers, and several author lists include company employees. That does not make them wrong, but replication by independent groups is thin.
• No lifespan data. The mouse study above measured markers of ageing, not survival; no human trial comes close.

The pattern will be familiar to anyone who followed resveratrol, another sirtuin-linked compound whose mouse data outran its human results - see resveratrol’s disappointing trials.

What the studies used

These are the amounts trials used, not a recommendation. Human trials have used 250 mg/day most often, with one dose-ranging study up to 900 mg/day for 60 days; all doses were taken orally once daily (or split twice daily), and NAD+ rose within a few weeks. No trial has established a dose that changes a health outcome, because no trial has measured one.

Safety

Short-term human studies report good tolerability with no serious adverse effects at studied doses. Long-term safety is simply unknown, and supplement quality and purity vary widely (NMN’s regulatory status has also been contested in the U.S.).

The regulatory history matters for quality. In late 2022 the FDA took the position that NMN could not be sold as a dietary supplement because it had already been authorised for investigation as a drug; in a letter dated September 2025 the agency reversed itself, concluding that NMN is not excluded from the definition of a dietary supplement, with confirmation letters to ingredient suppliers in December 2025. No regulator checks the content or purity of a given capsule before sale; third-party testing is the only way to know it contains what the label says.

Theoretical concerns that no trial has yet resolved:

• NAD+ is used by every cell, including abnormal ones, and some researchers have raised the question of whether long-term NAD+ boosting could feed unwanted cell growth. Nothing in the short human trials suggests this, but no trial has been long enough to see it.
• High-dose niacin (a related NAD+ precursor) causes flushing and can affect the liver; NMN trials up to 900 mg/day did not show this, but longer exposure is untested.

Talk to a clinician before taking NMN if you are pregnant or breastfeeding, have a history of cancer, take medications for diabetes (given the insulin-sensitivity signal), or have liver or kidney disease. None of the trials above was designed to answer questions about those groups.

For a checklist on reading trials like these, see how to read a supplement study.

Bottom line

NMN reliably raises NAD+ and looks safe short-term, but the leap from “raises a biomarker” to “makes you live longer or healthier” is not yet supported by strong human data. The best trials are 10–12 weeks long, have 25–80 participants, measure surrogates rather than outcomes and are mostly manufacturer-funded. It is a promising research area, not a proven anti-aging pill - so treat the marketing with skepticism and your dollars with caution.